GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lupin Ltd (NSE:LUPIN) » Definitions » Accounts Payable & Accrued Expense

Lupin (NSE:LUPIN) Accounts Payable & Accrued Expense : ₹33,983 Mil (As of Mar. 2025)


View and export this data going back to 2001. Start your Free Trial

What is Lupin Accounts Payable & Accrued Expense?

Lupin's quarterly accounts payable & accrued expense declined from Sep. 2024 (₹34,764 Mil) to Dec. 2024 (₹0 Mil) but then increased from Dec. 2024 (₹0 Mil) to Mar. 2025 (₹33,983 Mil).

Lupin's annual accounts payable & accrued expense increased from Mar. 2023 (₹39,403 Mil) to Mar. 2024 (₹46,134 Mil) but then declined from Mar. 2024 (₹46,134 Mil) to Mar. 2025 (₹33,983 Mil).

Lupin Accounts Payable & Accrued Expense Historical Data

The historical data trend for Lupin's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lupin Accounts Payable & Accrued Expense Chart

Lupin Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27,227.40 36,440.50 39,403.40 46,133.50 33,983.30

Lupin Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46,133.50 - 34,764.00 - 33,983.30

Lupin Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Lupin Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lupin Ltd (NSE:LUPIN) » Definitions » Accounts Payable & Accrued Expense
Comparable Companies
BOM:532321 BOM:543904 BOM:500124 NSE:TORNTPHARM NSE:AUROPHARMA BOM:500488 NSE:ALKEM BOM:500087 BOM:543064 BOM:532296 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
500257:India
Address
Off. Western Express Highway, 3rd floor, Kalpataru Inspire, Santacruz (East), Mumbai, MH, IND, 400055
Website
https://www.lupin.com
Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.

Lupin Headlines

No Headlines